At the 44th Annual J.P. Morgan Healthcare Conference, TransMedics CEO Waleed Hassanein outlined the company’s mission to expand organ preservation and transplantation. Hassanein emphasized that end-stage organ failure remains the most cost-effective yet underutilized therapy, noting current donor utilization rates have plateaued over the past four decades. He unveiled a rendering of TransMedics’ future headquarters in Somerville and confirmed a relocation timeline of 12 to 18 months, signaling confidence in mid-term operational and R&D scaling. CFO Gerardo fielded questions on capital allocation for next-generation Organ Care System enhancements and global adoption strategies, reinforcing the company’s pathway to increase transplant volumes worldwide.

TransMedics executed a long-term lease for a state-of-the-art global headquarters at Assembly Innovation Park in Somerville, Massachusetts, and acquired the adjacent parcel to establish an integrated campus. The facility will consolidate corporate, research, development and advanced manufacturing under one roof, with move-in scheduled on or before January 2028. The purpose-built space features large floor plates and specialized lab infrastructure designed to accelerate development of Warm Perfusion platforms. BioMed Realty, the campus developer, highlighted the building’s flexibility to support both production scale-up and clinical testing, enhancing TransMedics’ ability to shorten development cycles for its Organ Care System and related consumables.

The Commonwealth of Massachusetts, through the Massachusetts Life Sciences Center, proposed performance-based tax incentives worth up to $30,000 per new full-time position, capped at $18 million over 2026–2031, tied to a goal of creating up to 600 jobs. The City of Somerville supplemented this with a Tax Increment Financing package providing up to $18 million in property tax relief over ten years, projected to generate $75 million in local tax revenues. TransMedics anticipates adding 400 R&D, manufacturing and support roles by 2030 to staff its expanded campus. Governor Maura Healey and Lieutenant Governor Kim Driscoll underscored the alignment of these incentives with state life sciences priorities and the potential to strengthen Massachusetts’ leadership in transplant innovation.